NDAORALFOR SUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
E-Z-PAQUE (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
E-Z-PAQUE is an oral barium sulfate suspension used as a radiographic contrast agent to enhance visualization of the gastrointestinal tract during X-ray imaging. It works by increasing radiopacity in the GI tract, allowing clinicians to identify anatomical abnormalities and pathology. This non-absorbed, inert contrast medium is administered orally and excreted unchanged in stool.
Peak
E-Z-PAQUE is in peak commercial phase with established market presence; roles focus on maintaining share against iohexol competitors rather than growth expansion.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
Working on E-Z-PAQUE offers stable, established commercial experience in a mature diagnostic imaging market with defined workflows and healthcare provider relationships. Career growth is lateral (cross-product moves, account management) rather than vertical, as the product lifecycle offers limited expansion opportunity.
Worked on E-Z-PAQUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.